BOBO DONALD E JR 4

What Happened
Donald E. BoBo Jr, CVP, Strategy & Corporate Development at Edwards Lifesciences, exercised 22,680 derivative units (options) at $59.26 per share (cost $1,343,942) on April 2, 2026 and immediately sold those 22,680 shares in open-market transactions for total proceeds of about $1,818,055. The sales were executed in two reported blocks: 4,676 shares at a weighted average price of $80.59 (proceeds $376,846) and 18,004 shares at a weighted average price of $80.05 (proceeds $1,441,209). The filings indicate these transactions were effected under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: April 2, 2026 (filed same day; timely).
• Exercise: 22,680 shares at $59.26 (total exercise cost $1,343,942).
• Sales: 4,676 shares @ weighted avg $80.59 (prices ranged $80.510–$80.660) and 18,004 shares @ weighted avg $80.05 (prices ranged $79.490–$80.435); total sales ≈ $1,818,055.
• The Reporting Person sold the same number of shares as exercised (22,680), consistent with a cashless exercise/ immediate disposition.
• Footnotes: F1 = trades executed pursuant to a 10b5-1 plan adopted Feb 27, 2025; F2/F3 = sales executed in multiple trades with reported weighted averages; F4 = reference to 401(k) plan statement.
• Filing remarks: Form 4 reflects changes in beneficial ownership only and does not list other securities held by the reporting person.

Context
This was an exercise of derivatives followed by immediate open‑market sales (a common cashless exercise pattern). The use of a pre-established 10b5‑1 plan means the trades were made under a predetermined schedule, which can indicate routine disposition rather than a discretionary, market-timing decision. No information in this filing indicates a late report or that the reporting person is a >10% owner.